NCT01555242已完成1 期
A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Aneustat™ (OMN54) Administered on a Daily Oral Regimen in Patients With Advanced Cancer and Lymphomas
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 1
- 主要终点
- Maximum Tolerated Dose (MTD) of two dosing regimens (once daily and twice daily)
研究概览
简要总结
This is a phase I, open-label, multiple dose, dose escalation study to assess the safety, tolerability and pharmacokinetics of Aneustat™ (OMN54), a novel therapy, administered orally in patients with advanced cancer and lymphomas.
详细描述
Patients who complete a 28-day cycle, may be eligible to continue receiving Aneustat™ (OMN54) in 4-week increments for up to 6 cycles (inclusive of cycle 1) if further treatment is judged to be of possible benefit; if patient has not experienced unacceptable toxicity; and no study withdrawal criteria has been met.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological or cytological evidence of malignancy
- •Male or female, 18 years or older
- •Presence of advanced tumours, i.e., measurable or non-measurable disease (RECIST criteria, version 1.1)that have recurred or progressed following standard therapy
- •Able to swallow the oral capsule form of the drug
- •Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
- •Haematology within 7 days of Day 1 (initial dose):
- •Hemoglobin (Hb) > 9.0 g/dL
- •Platelets ≥ 100,000 cells/mm3 (or, ≥100 x 10/L)
- •Absolute neutrophil count (ANC) > 1.5 cells x109/L (or, > 1500 cells/mm3)
- •Chemistry within 7 days of Day 1 (initial dose):
- •AST(SGOT)/ALT(SGPT) ≤ 2.5 x ULN if no liver metastases, AST(SGOT)/ALT(SGPT) < 5 x ULN if liver metastases
- •Bilirubin < 1.5 x ULN unless Gilbert's Syndrome
- •Serum creatinine ≤ 1.25 ULN
- •Coagulation within 7 days of Day 1 (initial dose):
- •*INR ≤ 1.5
- •ECOG Performance Status between 0 - 2 and estimated life expectancy of > 3 months.
- •Having the initiative and means to be compliant with the protocol (as judged by the Principal Investigator) and is within a feasible geographical proximity of the study center to make the required study visits.
- •Written informed consent obtained prior to any study screening procedures
- •Females of childbearing potential (a female is considered of childbearing potential unless she is postmenopausal, i.e., no menses for at least 12 consecutive months, or is without a uterus) must have a negative urine pregnancy test (UPT) within 7 days of Day 1 (initial dose)
- •Females of childbearing potential must agree to use an effective method of contraception (i.e., sexual abstinence, condoms, intrauterine device, diaphragm) from Screening period and throughout study participation.
排除标准
- •Patient has uncontrolled or symptomatic brain metastases (If a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to Day 1 dosing).
- •Use of an investigational medication or device within 30 days of initiating study therapy (Day 1).
- •Major surgery within 30 days prior to first dose (Day 1).
- •Radiotherapy, chemotherapy, or immunotherapy within 28 days prior to Day 1 (not including palliative radiotherapy at focal sites).
- •Pregnancy or lactation.
- •Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (NY Heart Association Class III or IV, see Appendix 3), unstable angina pectoris, unstable cardiac arrhythmia, uncontrolled hypertension or psychiatric illness/social situations that would limit compliance with study requirements.
- •Screening (within approximately 28 days of registration) 12-lead electrocardiogram (ECG) that is abnormal and clinically significant
- •Refractory nausea and vomiting, chronic gastrointestinal diseases (e.g., inflammatory bowel disease), or significant bowel resection that would preclude adequate absorption.
- •Use of warfarin, i.e., Coumadin®, Jantoven® within 7 days prior to Day 1 (initial dosing)
- •Intolerance or aversion to porcine ingredients that are used for the OMN54 oral capsules in the investigational medicine, OMN54 (Aneustat™).
- •Known hypersensitivity to any of the three botanical constituents of Aneustat™ (OMN54), or other similar plants; or to plants belonging to Labiatae or Lamiaceae families, soy, or Aneustat™ (OMN54) excipients
- •Use of Sophora subprostrata root (SSR) or herba serissae within 14 days prior to Day 1.
研究组 & 干预措施
Aneustat (OMN54)
Experimental
干预措施: Aneustat (OMN54) (Drug)
结局指标
主要结局
Maximum Tolerated Dose (MTD) of two dosing regimens (once daily and twice daily)
The maximum tolerated dose (MTD) is defined as the dose, based on data from 6 patients (or 5 patients if one patient has withdrawn due to non-Aneustat (OMN54) related reasons), below the non-tolerated dose (DL T).
Dose Limiting Toxicity (DLT) of two dosing regimens (once daily and twice daily)
Assessment per Common Terminology Criteria for Adverse Events (CTCAE) v4.03.
Plasma blood concentrations of chemical markers
These measurements are intended to characterize the pharmacokinetics of Aneustat (OMN54)
次要结局
- Tumor Response
- Measurement of pathway biomarkers in plasma
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of CS1001 in Subjects With Advanced Solid TumorsAdvanced Solid TumorsNCT03744403CStone Pharmaceuticals24
终止
1 期
A Study of CS3002 in Subjects With Advanced Solid TumorsAdvanced Solid TumorNCT04162301CStone Pharmaceuticals10
招募中
1 期
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.CLL/SLLWaldenstrom MacroglobulinemiaDiffuse Large B Cell LymphomaMarginal Zone LymphomaHairy Cell LeukemiaMantle Cell LymphomaFollicular LymphomaNCT04775745Newave Pharmaceutical Inc60
招募中
1 期
Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.High-grade GliomaWHO Grade Ⅳ GliomaNCT06482905Tcelltech Inc.52
招募中
1 期
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid TumorsAdvanced Solid TumorSubcutaneous TumorMalignant Solid TumorSolid TumorMetastatic Solid TumorMetastasis to Soft TissueNon Small Cell Lung CancerCutaneous Squamous Cell CarcinomaCutaneous TumorNCT06171750Ankyra Therapeutics, Inc97